Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Intrinsic Value
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. [ Read More ]
The intrinsic value of one ARDS stock under the Base Case scenario is 10.0568 USD. Compared to the current market price of 0.0747 USD, Aridis Pharmaceuticals Inc is Undervalued by 99%.
Fundamental Analysis
Balance Sheet Decomposition
Aridis Pharmaceuticals Inc
Current Assets | 4.1m |
Cash & Short-Term Investments | 35k |
Receivables | 517k |
Other Current Assets | 3.6m |
Non-Current Assets | 2.4m |
PP&E | 1.6m |
Intangibles | 13k |
Other Non-Current Assets | 827k |
Current Liabilities | 17.5m |
Accounts Payable | 8.8m |
Accrued Liabilities | 8.3m |
Other Current Liabilities | 395k |
Non-Current Liabilities | 854k |
Other Non-Current Liabilities | 854k |
Earnings Waterfall
Aridis Pharmaceuticals Inc
Revenue
|
22.4m
USD
|
Operating Expenses
|
-23.2m
USD
|
Operating Income
|
-883k
USD
|
Other Expenses
|
-259k
USD
|
Net Income
|
-1.1m
USD
|
Free Cash Flow Analysis
Aridis Pharmaceuticals Inc
What is Free Cash Flow?
ARDS Profitability Score
Profitability Due Diligence
Aridis Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Aridis Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
ARDS Solvency Score
Solvency Due Diligence
Aridis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Aridis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARDS Price Targets Summary
Aridis Pharmaceuticals Inc
Ownership
ARDS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ARDS Price
Aridis Pharmaceuticals Inc
Average Annual Return | -30.19% |
Standard Deviation of Annual Returns | 43.63% |
Max Drawdown | -100% |
Market Capitalization | 3.3m USD |
Shares Outstanding | 44 574 000 |
Percentage of Shares Shorted | 6.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California and currently employs 34 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The firm's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.